DU Xiaofeng,ZHANG Yayue,ZHAO Hongbin,et al.Jianpi Yiqi Shexue Formula in treatment of thrombocytopenia after CAR-T for diffuse large B-cell lymphoma[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(04):529-533.
DU Xiaofeng,ZHANG Yayue,ZHAO Hongbin,et al.Jianpi Yiqi Shexue Formula in treatment of thrombocytopenia after CAR-T for diffuse large B-cell lymphoma[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(04):529-533.DOI: 10.16025/j.1674-1307.2026.04.021.
Jianpi Yiqi Shexue Formula in treatment of thrombocytopenia after CAR-T for diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 10%–15% of cases are refractory, and 30%–40% of patients relapse after first-line treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) provides a new therapeutic option for relapsed and refractory DLBCL; however, it may induce cancer treatment-induced thrombocytopenia (CTIT), thereby limiting its clinical application. In traditional Chinese medicine (TCM), thrombocytopenia after CAR-T therapy belongs to the category of "drug toxin-induced purpura". The team led by Professor CHEN Xinyi at Dongzhimen Hospital of Beijing University of Chinese Medicine developed the
Jianpi Yiqi Shexue Formula
based on the therapeutic principle of "strengthening the spleen, replenishing
qi
, and securing blood" for the treatment of myelosuppression primarily man
ifested as thrombocytopenia. The formula demonstrates correspondence among formula patterns, medicinal patterns, and disease patterns, conforms to the pathogenesis of the spleen failing to control blood, and has shown certain effects in increasing platelet counts.
关键词
Keywords
references
BERG MJTEN , VAN DEN BEMT PM , SHANTAKUMAR S , et al . Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study [J ] . Drug Saf , 2011 , 34 ( 12 ): 1151 - 1160 .
CORDEIRO A , BEZERRA ED , HIRAYAMA AV , et al . Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells [J ] . Biol Blood Marrow Transplant , 2020 , 26 ( 1 ): 26 - 33 .
BAUR R , JITSCHIN R , KHARBOUTLI S , et al . Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report [J ] . J Immunother Cancer , 2021 , 9 ( 7 ): e002721 .